Company profile
Cell Source, Inc. CIK 1569340
Industry
Pharmaceutical Preparations
Headquarters
New York, NY 10019
Fiscal year end
2024 (FY)
Key Financials
Revenue
—
Net income
-$4.51M
Total assets
$286.5K
Total liabilities
$18.82M
Stockholders' equity
-$18.54M
Cash & equivalents
$74.6K
Operating income
-$3.84M
Operating cash flow
-$2.68M
Capital expenditures
—
Fiscal year 2024, via 10-K filed 2026-04-07. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
6,570.4%
Equity / assets
-6,470.4%
CapEx / revenue
—
Operating cash flow / net income
0.59×
Derived from the fiscal year 2024 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2024
—
-$4.51M
$286.5K
$18.82M
-$18.54M
2023
—
-$5.32M
$195.2K
$15.81M
-$15.61M
2022
—
-$5.17M
$409.8K
$13.04M
-$12.63M
2021
—
-$5.47M
$313.8K
$10.14M
-$9.83M
2020
—
-$4.56M
$452.3K
$8.40M
-$7.95M
Company Details
SIC code
2834
State of incorporation
NV
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-05-14
Financials filed via
Form 10-K
filed 2026-04-07
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
New York, NY 10019
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:44 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.